Drug Trial Radar · NCT06710132
Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
184
Actual
Start
Jan 29, 2025
Primary completion
Dec 23, 2027
Study completion Dec 23, 2027
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany; Merck KGaA, Darmstadt, Germany
- First posted
- Nov 29, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The PROCEADE PanTumor study aims to investigate M9140 in multiple tumor types which express carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) and it is therefore designed as a matrix study. This study aims to assess the antitumor activity, tolerability, safety, and pharmacokinetics (PK) of M9140 as monotherapy or in combination treatments in adult participants with locally advanced/metastatic CEACAM5 expressing tumors. There will be 3 substudies under this Master Protocol that may be conducted in parallel. * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Gastric Cancer (Substudy GC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open-Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants with Advanced Non-Small Cell Lung Cancer (Substudy NSCLC); * PROCEADE PanTumor: A Phase 1b/2, Multicenter, Open Label Study of Anti-CEACAM5 Antibody-Drug Conjugate M9140 in Participants With Advanced Pancreatic Cancer (Substudy PDAC).
Conditions
- Solid Tumors
- Gastric Cancer
- Non-Small Cell Lung Cancer (NSCLC)
- Pancreatic Cancer
- Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
M9140Drug
All participants will receive 2.8 milligram per kilogram (mg/kg) M9140 intravenously (i.v.) every 3 weeks (q3w) on Day 1 of consecutive 21-day cycles.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Substudies GC/NSCLC/PDAC: Objective Response (OR) According to Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST v1.1) as Assessed by InvestigatorsTime frame: Time from first study treatment to (planned) final assessment at approximately 48 months
Locations
81 sites in 10 countries. Site status is shown where the registry gives one.
University of California - Los Angeles - 300208353
Santa Monica, California
Providence Medical Foundation
Santa Rosa, California
Georgetown University - Lombardi Comprehensive Cancer Center - 1134847
Washington D.C., District of Columbia
D&H Cancer Research Center
Margate, Florida
Prisma Health Cancer Institute, ITOR, CRU
Greenville, South Carolina
Baptist Cancer Center
Memphis, Tennessee
The University of Texas MD Anderson Cancer Center
Houston, Texas
NEXT Virginia
Fairfax, Virginia
Flinders Medical Centre
Bedford Park, Australia
Nepean Cancer Care Centre
Kingswood, Australia
Mater Misericordiae Ltd - PARENT
South Brisbane, Australia
Macquarie University Hospital - PARENT
Sydney, Australia
Ordensklinikum Linz Krankenhaus der Elisabethinen Linz - Pneumology
Linz, Austria
LKH - Universitätsklinikum der PMU Salzburg - Innere Med III/Hämatologie und Onkologie
Salzburg, Austria
Medical University of Vienna - Department of Internal Medicine
Vienna, Austria
Anhui Provincial Cancer Hospital
Hefei, Anhui, China
Beijing Cancer Hospital
Beijing, Beijing Municipality, China
Sun Yat-sen University Cancer Center
Guangzhou, Guangzhou, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hebei, China
Harbin Medical University Cancer Hospital
Harbin, Heilongjiang, China
Xiangya Hospital, Central South University
Changsha, Hu'nan, China
Tongji Hospital, Tongji Medical College, Huazhong University of Science & Technology
Wuhan, Hubei, China
Sichuan Cancer Hospital
Chengdu, Sichuan, China
West China Hospital, Sichuan University
Chengdu, Sichuan, China
Sir Run Run Shaw Hospital, Zhejiang University School of Medicine - Department of Oncology Surgery
Hangzhou, Zhejiang, China
Institut Bergonié - Service d'Oncologie Médicale
Bordeaux, France
Centre Georges François Leclerc - Unité de Phase I
Dijon, France
Centre Oscar Lambret - cancerologie generale
Lille, France
Hopital Albert Calmette - CHU Lille - CHU Lille - Institut Coeur Poumon
Lille, France
Hôpital Européen Georges Pompidou - Hématologie Oncologie
Paris, France
Hôpital Saint-Antoine - Oncologie Médicale
Paris, France
ICO - Site René Gauducheau - Service d'Oncologie medicale
Saint-Herblain, France
Hôpital Foch - Service d'Oncologie Médicale
Suresnes, France
Institut Claudius Regaud - Service d'oncologie médicale
Toulouse, France
Institut Gustave Roussy - Pathologie Thoracique
Villejuif, France
Charité - Campus Charité Mitte - Charité Comprehensive Cancer Center
Berlin, Germany
Krankenhaus Nordwest GmbH - Neurologische Klinik
Frankfurt am Main, Hesse, Germany
St. Josef-Hospital im Katholischen Klinikum Bochum - Haematologie, Onkologie und Palliativmedizin
Bochum, North Rhine-Westphalia, Germany
Universitaetsmedizin der Johannes Gutenberg-Universitaet Mainz - I. Medizinische Klinik Gastroenterologie u Hepato.
Mainz, Rhineland-Palatinate, Germany
Universitaetsklinikum Carl Gustav Carus TU Dresden - Medizinische Klinik I
Dresden, Saxony, Germany
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.